- Home
- JILL vs TSHA Comparison
JILL vs TSHA Comparison
Compare JILL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JILL
- TSHA
- Stock Information
- Founded
- JILL 1959
- TSHA 2019
- Country
- JILL United States
- TSHA United States
- Employees
- JILL N/A
- TSHA N/A
- Industry
- JILL Clothing/Shoe/Accessory Stores
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- JILL Consumer Discretionary
- TSHA Health Care
- Exchange
- JILL Nasdaq
- TSHA Nasdaq
- Market Cap
- JILL N/A
- TSHA 397.8M
- IPO Year
- JILL 2017
- TSHA 2020
- Fundamental
- Price
- JILL $15.82
- TSHA $2.10
- Analyst Decision
- JILL Strong Buy
- TSHA Strong Buy
- Analyst Count
- JILL 5
- TSHA 8
- Target Price
- JILL $36.20
- TSHA $6.63
- AVG Volume (30 Days)
- JILL 84.3K
- TSHA 2.9M
- Earning Date
- JILL 06-06-2025
- TSHA 05-16-2025
- Dividend Yield
- JILL 1.44%
- TSHA N/A
- EPS Growth
- JILL 3.98
- TSHA N/A
- EPS
- JILL 2.61
- TSHA N/A
- Revenue
- JILL $610,857,000.00
- TSHA $8,333,000.00
- Revenue This Year
- JILL $3.91
- TSHA N/A
- Revenue Next Year
- JILL $3.30
- TSHA N/A
- P/E Ratio
- JILL $5.84
- TSHA N/A
- Revenue Growth
- JILL 0.46
- TSHA N/A
- 52 Week Low
- JILL $14.37
- TSHA $1.05
- 52 Week High
- JILL $40.61
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- JILL 45.10
- TSHA 58.01
- Support Level
- JILL $14.64
- TSHA $1.85
- Resistance Level
- JILL $16.12
- TSHA $2.73
- Average True Range (ATR)
- JILL 0.61
- TSHA 0.27
- MACD
- JILL 0.23
- TSHA 0.04
- Stochastic Oscillator
- JILL 79.67
- TSHA 58.47
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.